Biodesix (BDSX) Total Non-Current Liabilities (2019 - 2026)

Biodesix (BDSX) has 8 years of Total Non-Current Liabilities data on file, last reported at $71.0 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 14.79% year-over-year to $71.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71.0 million (up 14.79% YoY) and the FY2025 annual result came in at $72.5 million, up 16.85% from the prior year.
• Total Non-Current Liabilities retreated to $71.0 million in Q1 2026, from $72.5 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $72.5 million in Q4 2025 to a low of $24.1 million in Q1 2022.
• A 5-year average of $56.5 million and a median of $61.5 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities sank 61.77% — and 2023, when it jumped 125.05%.
• Tracing BDSX's Total Non-Current Liabilities over 5 years: stood at $49.5 million in 2022, then climbed by 23.53% to $61.1 million in 2023, then climbed by 1.56% to $62.1 million in 2024, then climbed by 16.85% to $72.5 million in 2025, then decreased by 2.05% to $71.0 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $71.0 million (Q1 2026), $72.5 million (Q4 2025), and $72.3 million (Q3 2025), per Business Quant data.